Skylands Capital LLC Has $3.97 Million Stock Holdings in Haemonetics Corporation $HAE

Skylands Capital LLC grew its position in Haemonetics Corporation (NYSE:HAE) by 195.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 81,369 shares of the medical instruments supplier’s stock after buying an additional 53,819 shares during the period. Skylands Capital LLC owned 0.17% of Haemonetics worth $3,966,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HAE. EverSource Wealth Advisors LLC boosted its holdings in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the last quarter. Versant Capital Management Inc lifted its position in Haemonetics by 216.4% during the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 567 shares during the period. Byrne Asset Management LLC bought a new position in shares of Haemonetics in the 3rd quarter valued at about $42,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Haemonetics during the 2nd quarter worth approximately $64,000. Finally, Hantz Financial Services Inc. grew its position in shares of Haemonetics by 792.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 998 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $59.47 on Wednesday. The stock’s fifty day simple moving average is $75.95 and its 200 day simple moving average is $64.81. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $2.76 billion, a PE ratio of 16.38, a PEG ratio of 1.21 and a beta of 0.28. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. During the same period in the prior year, the company earned $1.19 earnings per share. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on HAE shares. Citigroup cut their price objective on shares of Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a report on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. Mizuho cut their price target on Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a research note on Friday. BTIG Research reaffirmed a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research note on Friday, February 6th. Finally, CJS Securities upgraded Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $84.44.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.